Cue Biopharma legal chief sells $265,627 in common stock By Investing.com

Sumita Ray, Chief Legal Compliance Officer and Corporate Secretary at Cue Biopharma, Inc. (), sold 8,829 shares of the company’s common stock on August 13, 2026, for a total value of $265,627. These sales followed Ray’s acquisition of 18,196 shares of common stock through the exercise of derivative securities.

The sales were executed at prices ranging from $29.37 to $31.13 per share. These transactions were identified as “sell-to-cover” sales, intended to satisfy tax withholding obligations in connection with the vesting and settlement of performance stock units, and do not represent discretionary transactions by the reporting person. The stock’s remarkable 210% surge over the past six months helps explain why these price-based PSUs are now vesting, according to InvestingPro data, which also reveals the company remains undervalued based on Fair Value analysis. The prices reported for some of these sales were weighted average prices, with shares sold as part of block trades at various prices within specified ranges.

The 18,196 shares acquired originated from the vesting of performance stock units (PSUs). These PSUs were awarded subject to certain stock-price based vesting conditions, with this tranche vesting upon the achievement of a closing price per share of $33.00 for five consecutive trading days. This award settled with respect to one-third of the total PSUs on August 13, 2026. The remaining two-thirds of the PSUs are expected to vest upon the achievement of closing prices of $38.50 and $44.00, respectively, each for a period of five consecutive trading days. If these targets are not met within 24 months from the date of grant, the PSUs will be forfeited. For deeper insights into CUE’s valuation and performance metrics, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.

In other recent news, Cue Biopharma has announced several significant developments. The company raised approximately $50 million through a private placement with accredited investors. This financial move involves issuing over 1.4 million shares of common stock and pre-funded warrants for additional shares. In leadership changes, Dominic Borie, M.D., Ph.D., has been appointed as the new Chief Medical Officer and Head of Research & Development, reporting directly to CEO Shao-Lee Lin, M.D., Ph.D. Additionally, Cue Biopharma’s board of directors has undergone restructuring with the resignation of four independent directors: Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen. To fill these vacancies, the company appointed Daniel Camardo and Viola Meehan as new board members. These changes occur as the company continues to develop therapies for immune-mediated diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.